Clinical Trials for Acute Lymphoblastic Leukemia, in Relapse

Find clinical trials for acute lymphoblastic leukemia, in relapse. Discover research opportunities and treatment options in your area.

20 Active Trials Found

Showing 20 trials on this page

Page 1 of 1

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

NCT ID: NCT04881240

This clinical trial is studying a new type of treatment called CD19-directed allogeneic memory T-cell therapy for children and young adults up to 21 years old who have leukemia that has come back o...

Recruiting

Phase: PHASE1 Type: interventional Locations: Memphis, Tennessee, United States

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

NCT ID: NCT07070323

This clinical trial is testing a new kind of treatment called CD5 CAR T-cell therapy for people with certain hard-to-treat blood cancers that affect T-cells, a type of immune cell. These cancers ha...

Recruiting

Phase: PHASE1 Type: interventional Locations: Chengdu, Sichuan, China, Beijing, Beijing, China +2 more

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

NCT ID: NCT05779930

This clinical trial is looking at a new treatment using a special type of immune cell therapy called CAR T cells for children and young adults with certain types of blood cancers, specifically rela...

Not yet recruiting

Phase: EARLY_PHASE1 Type: interventional Locations: Columbus, Ohio, United States

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT ID: NCT05292664

The Venetoclax Basket Trial is a research study aimed at testing the safety and effectiveness of a medication called venetoclax in combination with chemotherapy for young patients facing serious bl...

Recruiting

Phase: PHASE1 Type: interventional Locations: Boston, Massachusetts, United States, Aurora, Colorado, United States +3 more

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

NCT ID: NCT06034561

This clinical trial is studying a treatment regimen that includes a medication called bortezomib for adults with acute lymphoblastic leukemia (ALL) that has either come back after treatment (relaps...

Recruiting

Phase: PHASE2 Type: interventional Locations: São Paulo, Sp, Brazil

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies

NCT ID: NCT06316427

This clinical trial is investigating a new treatment for patients with a type of leukemia called T-cell acute lymphoblastic leukemia (T-ALL) or lymphoma that has not responded to standard therapies...

Recruiting

Phase: PHASE1 Type: interventional Locations: Chengdu, Sichuan, China, Beijing, Beijing, China +2 more

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects with Relapsed or Refractory T-cell Malignancies

NCT ID: NCT06316856

This clinical trial is studying a new type of treatment called CD5 Chimeric Antigen Receptor (CAR) T cell therapy for patients with a type of cancer known as relapsed or refractory T-cell acute lym...

Recruiting

Phase: PHASE1 Type: interventional Locations: Chengdu, Sichuan, China, Beijing, Beijing, China +2 more

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

NCT ID: NCT06343090

This clinical trial is investigating two different treatments for children and young adults with a type of leukemia called B-cell Acute Lymphoblastic Leukemia (B-ALL) that has come back or has not ...

Recruiting

Phase: NA Type: interventional Locations: Beijing, Beijing, China

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

NCT ID: NCT06213636

This clinical trial is exploring a new treatment using advanced CAR T cells, which are specially modified immune cells, to help patients with certain types of difficult-to-treat cancers, particular...

Recruiting

Phase: PHASE1 Type: interventional Locations: Manama, , Bahrain, Shanghai, , China +1 more

HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies

NCT ID: NCT05658640

The HEM iSMART-D clinical trial is exploring a new treatment approach for children and young adults with certain types of blood cancers, specifically acute lymphoblastic leukemia (ALL) and lymphobl...

Recruiting

Phase: PHASE1 Type: interventional Locations: Turin, , Italy, Barcelona, , Spain +34 more

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

NCT ID: NCT06326008

This clinical trial is studying a new treatment approach for children and young adults with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), a type of blood cancer. The trial aim...

Not yet recruiting

Phase: PHASE1 Type: interventional

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

NCT ID: NCT06641024

This clinical trial is studying a new treatment option for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. The researchers want to see if a s...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Shanghai, , China

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT ID: NCT05745714

The HEM-iSMART-C clinical trial is studying a combination of medications to find out if they are safe and effective for children and young adults with certain types of blood cancers, specifically t...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Utrecht, , Netherlands, Utrecht, , Netherlands

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

NCT ID: NCT06445803

This clinical trial is studying a new treatment using specially modified immune cells, called CAR-T cells, to help adults with certain types of blood cancers, specifically relapsed or refractory ac...

Recruiting

Phase: PHASE1 Type: interventional Locations: Shanghai, Shanghai, China, Shanghai, , China +1 more

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

NCT ID: NCT05310591

This clinical trial is studying a new treatment approach for children, adolescents, and young adults aged 1 to 25 years who have a type of blood cancer called Acute Lymphoblastic Leukemia (B-ALL) t...

Recruiting

Phase: PHASE1 Type: interventional Locations: Nancy, , France, Lille, , France +10 more

Determining the Mechanisms of Loss of CAR T Cell Persistence

NCT ID: NCT05809284

This clinical trial is looking at how well a type of treatment called CAR T-cell therapy works for patients with a specific type of blood cancer known as acute lymphoblastic leukemia (ALL) who have...

Recruiting

Type: observational Locations: Manchester, , United Kingdom, London, , United Kingdom +1 more

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

NCT ID: NCT06389305

This clinical trial is studying a new treatment called CIK cell therapy for children and young adults with relapsed or refractory acute B-lymphoblastic leukemia (B-ALL). This is a type of cancer th...

Not yet recruiting

Phase: NA Type: interventional Locations: Beijing, Beijing, China

Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO

NCT ID: NCT06025682

This clinical trial is looking at how often patients with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) develop infections after receiving a specific treatment known as ...

Recruiting

Type: observational Locations: Roma, , Italy

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

NCT ID: NCT05705570

This clinical trial is testing a new treatment for patients with certain types of blood cancers, specifically those that are difficult to treat or have come back after previous therapies. The study...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: São Paulo, , Brazil

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

NCT ID: NCT04603872

This clinical trial is examining a new treatment option for patients with certain types of blood cancers, specifically those who have had their cancer come back or haven’t responded to previous tre...

Recruiting

Phase: EARLY_PHASE1 Type: interventional Locations: Hangzhou, Zhejiang, China

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions